Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.65 |
| ▸ | CTSS | P25774 | 4/20 | 0.61 |
| ▸ | PPARG | P37231 | 2/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KLK7 | P49862 | 2/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1132570 | 1.00 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL212797 | 1.00 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL18407225 | 0.93 | PPARA (0.69) | PPARACTSSPPARGATMSYK | |
| SCHEMBL31266138 | 0.90 | PPARA (0.62) | PPARACTSSPPARGATMSYK | |
| SCHEMBL31048314 | 0.90 | PPARA (0.62) | PPARACTSSPPARGATMSYK | |
| SCHEMBL25467757 | 0.90 | PPARA (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL27538401 | 0.90 | ATM (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL903406 | 0.90 | ATM (0.65) | PPARACTSSPPARGATMSYK | |
| SCHEMBL397123 | 0.88 | PPARA (0.63) | PPARACTSSPPARGATMSYK | |
| SCHEMBL740897 | 0.88 | PPARA (0.63) | PPARACTSSPPARGATMSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916790-A | Pyrido [2,3-b ] [1,4] oxazines or tetrahydropyrido [2,3-b ] [1,4] oxazepines as IAP antagonists | 百济神州有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114667167-A | Heterocyclic compounds for the treatment of cancer | 阿提奥斯医药有限公司 | 2022-06-24 | — | — | CN | disclosed |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | VERA THERAPEUTICS INC (US) | 2021-07-08 | — | — | US | disclosed |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | VERA THERAPEUTICS INC (US) | 2021-06-10 | — | — | US | disclosed |
| CN-112469725-A | Penicillin binding protein inhibitors | 维纳拓尔斯制药公司 | 2021-03-09 | — | — | CN | disclosed |
| EP-3601237-A2 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | Trucode Gene Repair, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110740994-A | Peptide Nucleic Acid (PNA) monomers with orthogonally protected ester moieties | 特鲁科德基因修复公司 | 2020-01-31 | — | — | CN | disclosed |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | NEUBASE THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | JAPAN TOBACCO INC. (JP) | 2018-11-08 | — | — | US | disclosed |
| US-20180282375-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | NEUBASE THERAPEUTICS, INC. | 2018-10-04 | — | — | US | disclosed |
| WO-2004084843-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-6720338-B2 | BCL-X1 INHIBITING COMPOSITIONS AND METHODS OF PROMOTING APOPTOSIS IN A MAMMAL | ABBOTT LABORATORIES | 2004-04-13 | — | — | US | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| CN-1440400-A | Bicyelyl or heterobicyclylmethanesulfonylamino-substituted N-hydroxyformamides | SMITHKLINE BEECHAMP P L C (GB) | 2003-09-03 | — | — | CN | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | ABBVIE INC. | 2002-07-04 | — | — | US | disclosed |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | ABBOTT LABORATORIES | 2002-05-09 | — | — | US | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| CN-1171112-A | Amino acid nucleic acids | ICN PHARMACEUTICALS CO (US) | 1998-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020086887-A1 | N-Acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | PPARA 2308/4885CTSS 673/4885PPARG 2763/4885 |
| US-20180319798-A1 | 1,3,4,8-Tetrahydro-2H-Pyrido[1,2-a]Pyrazine Derivative and Use of the Same as HIV Integrase Inhibitor | IMPA1, IMPDH1, TYMP | PPARA 1795/4885CTSS 3308/4885PPARG 2628/4885 |
| US-20190055190-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | PPARA 1015/4885CTSS 2732/4885PPARG 1668/4885 |
| US-20020055631-A1 | N-acylsulfonamide apoptosis promoters | BAX, BCLAF1, BCL2 | PPARA 2014/4885CTSS 876/4885PPARG 2503/4885 |
| US-20180282375-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | PPARA 1312/4885CTSS 3209/4885PPARG 1425/4885 |
| US-20210171437-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY AND NOVEL INTERMEDIATES AND METHODS RELATED THERETO | TARBP1, TIA1, SSB | PPARA 1015/4885CTSS 2732/4885PPARG 1668/4885 |
| US-20210206809-A1 | PEPTIDE NUCLEIC ACID (PNA) MONOMERS WITH AN ORTHOGONALLY PROTECTED ESTER MOIETY | AGO2, TARBP1, TPR | PPARA 1312/4885CTSS 3209/4885PPARG 1425/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | PPARA 4589/4885CTSS 807/4885PPARG 4630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.